Physician profile
Amer G Aboukasm
NPI 1194754085
$2,699.47
in general payments reported to CMS, 2019-2025
34 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,251 · 2020: $310 · 2024: $17.08 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $372.89 | 2019 | |
| Biogen, INC. | $235.72 | 2019 | |
| Acadia Pharmaceuticals INC | $200.18 | 2019-2020 | |
| Genentech USA, INC. | $133.79 | 2019-2020 | |
| Ucb, INC. | $133.23 | 2019-2020 | |
| Eisai INC. | $122.21 | 2019 | |
| Jazz Pharmaceuticals INC. | $121.17 | 2025 | |
| Acorda Therapeutics, INC | $107.65 | 2019 | |
| Akcea Therapeutics, INC. | $107.49 | 2019 | |
| Allergan, INC. | $101.66 | 2019-2020 | |
| Medtronic USA, INC. | $80.87 | 2019-2020 | |
| Greenwich Biosciences, INC. | $78.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $77.48 | 2019-2020 | |
| Mdd US Operations, LLC | $76.11 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $73.36 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $72.11 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $63.31 | 2019 | |
| Alexion Pharmaceuticals, INC. | $62.22 | 2019 | |
| Validus Pharmaceuticals LLC | $59.69 | 2019 | |
| Adamas Pharmaceuticals, INC. | $52.83 | 2019 | |
| Lilly USA, LLC | $46.72 | 2019 | |
| Alnylam Pharmaceuticals INC. | $44.31 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $42.46 | 2019 | |
| Harmony Biosciences LLC | $42.27 | 2020 | |
| Genzyme Corporation | $42.26 | 2019 | |
| Abbvie INC. | $21.02 | 2019 | |
| Bausch Health US, LLC | $18.14 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.28 | 2019 | |
| Celgene Corporation | $17.08 | 2024 | Zeposia |
| Amgen INC. | $17.06 | 2019 | |
| Csl Behring | $16.17 | 2019 | |
| Neurocrine Biosciences, INC. | $15.36 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.94 | 2019 | |
| Zyla Life Sciences, INC. | $12.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Aboukasm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.